Skip to content

Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery

Effect of Cyclosporine and Remote Ischemic Preconditioning on MDA, Calcium Cytosol Concentration, and Mitochondrial Edema in Reperfusion Ischemia Injury: Research on Tetralogy Fallot Patients With Correction Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05691764
Enrollment
40
Registered
2023-01-20
Start date
2020-09-01
Completion date
2022-09-01
Last updated
2023-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery, Myocardial Injury

Keywords

RIPC, cyclosporine, ischemia reperfusion injury, MDA, calcium cytosol, tetralogy Fallot, mitochondrial edema, infundibulum

Brief summary

The study aimed to evaluate the combined effects of cyclosporine and remote ischemic preconditioning on MDA, calcium cytosol concentration, and mitochondrial edema in tetralogy Fallot patients undergoing corrective surgery.

Detailed description

Forty patients undergoing tetralogy Fallot corrective surgery were randomized to RIPC and cyclosporine (n=20) and control (n=20). Cyclosporin was administered 2 hour pre induction of anesthesia with the dose of 3 mg/kg body weight intravenously. RIPC was performed preoperatively after induction of anesthesia by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval. Blood samples from coronary sinus and biopsies from the myocardial infundibulum were obtained three times at the condition of pre ischemic, ischemic, and reperfusion. MDA was measured from the blood samples, meanwhile calcium cytosol concentration and mitochondrial edema was measured from the biopsy samples.

Interventions

Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight

PROCEDUREremote ischemic preconditioning

Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval

DRUGPlacebo

Intravenous placebo

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

* Tetralogy Fallot patient that is undergoing correction surgery * Has an ideal anatomy for corrective surgery, namely: Pulmonary artery size within normal limits (according to the kirklin table), Mc Goon ratio\> 1.5, Nakata index\> 200, normal coronary artery ostium and good biventricular function.

Exclusion criteria

* Patient refuses the procedure * Patient with acute kidney injury * Patient without lower extremity * Patient with cyclosporin allergy

Design outcomes

Primary

MeasureTime frameDescription
Malondialdehyde (MDA)1 yearROS level is determined by measuring MDA concentration (nmol/mL)
Calcium cytosol concentration1 yearCalcium concentration (nmol/mL) in cytosol is determined by ratiometric analysis on Fura Red- dyed heart cells.
Mitochondrial edema1 yearMitochondrial edema (%) is measured by decreasing of optical density that indicates change in mitochondrial matrix volume.

Secondary

MeasureTime frameDescription
Cardiac index1 yearExamined with echocardiography, unit of measurement is litres per minute per square metre (L/min/m2).
Troponin I1 yearMeasured from venous blood, unit of measurement is nanograms per milliliter (ng/mL).
Creatine kinase- MB (CKMB)1 yearMeasured from venous blood, unit of measurement is units per liter (IU/L).
Vasoactive inotropic score (VIS)1 yearVIS was calculated as: dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min) + 10 × milrinone dose (μg/kg/min) + 10 000 × vasopressin dose (unit/kg/min) + 100 × norepinephrine dose (μg/kg/min).

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026